Last updated: April 2, 2026
What is the Medical and Commercial Profile of NDC 69238-1137?
NDC 69238-1137 is marketed as Brilinta (ticagrelor). Approved by the FDA in 2011, Brilinta is an oral antiplatelet agent used to reduce the risk of cardiovascular events in patients with acute coronary syndromes (ACS) and myocardial infarction (MI). It is manufactured by AstraZeneca.
This drug's primary competition includes Plavix (clopidogrel), Effient (prasugrel), and Brilinta itself. It occupies a clinical niche emphasizing faster onset and reversible platelet inhibition.
Market Size and Dynamics
Market Position
Brilinta's popularity hinges on its pharmacodynamics, including reversibility and rapid onset, for secondary prevention of cardiovascular events.
Total Addressable Market (TAM)
- US Cardiovascular Disease (CVD) Market: The American Heart Association projects over 18 million Americans diagnosed with ACS annually.
- Patients Eligible for Antiplatelet Therapy: Estimated at 70% of ACS cases, accounting for approximately 12.6 million patients per year in the US.
- Global Market: The global market for antiplatelet drugs exceeds $7 billion in 2022, with a compound annual growth rate (CAGR) of around 4%.
Prescription Trends
Brilinta’s prescriptions have grown steadily since launch, with a 2022 US market share estimated at 25% among P2Y12 inhibitors, largely due to its clinical benefits profile.
Price Benchmarking
The average wholesale price (AWP) for a 90-tablet supply (90 mg twice daily) typically ranges between $200 and $300, depending on distribution channels and discounts.
| Parameter |
Estimate/Value |
| US Market Share (2022) |
25% among P2Y12 inhibitors |
| US Annual Volume |
~2.5 million units (approximated) |
| Wholesale Price per 90 tablets |
$220–$280 |
Competitive Landscape
| Drug |
Class |
Market Share (2022) |
Key Features |
Price Range (per pack) |
| Brilinta |
Ticagrelor |
25% |
Reversibility, rapid onset |
$220–$280 |
| Plavix |
Clopidogrel |
~50% |
Established, off-patent |
$150–$200 |
| Effient |
Prasugrel |
~15% |
Used in specific cases |
$250–$300 |
Price Projections
Short-Term (Next 1–2 Years)
- Stable Pricing: Given existing contractual agreements and patent exclusivity, prices are unlikely to fluctuate significantly barring policy changes.
- Potential Discounts: Managed markets could see discounts up to 15%, especially in government programs like Medicaid and Medicare.
Medium-Term (3–5 Years)
- Patent Expiry: Brilinta's patent protection expires in 2024 in the US, opening market share for generics.
- Generic Entry Impact: Price drops of 40–60% anticipated post-generic approval, potentially reducing the price per pack to $100–$150.
- Market Share Redistribution: Generics may capture 60–80% of the prescription volume, affecting revenue projections.
Long-Term (5+ Years)
- Market Penetration of Generics: Post-generic entry, the branded drug will see diminished revenue unless differentiated offering or formulation changes occur.
- Emerging Therapies: New antiplatelet agents or alternative therapies could supplant Brilinta, decreasing its market size by projected 10–20% annually after patent expiry.
Regulatory and Market Risks
- Patent Litigation: Any delays or disputes could impact generic entry timelines.
- Pricing Regulations: Policy efforts to control drug prices could further lower prices, especially under government programs.
- Clinical Results: New trials or comparative studies may alter prescribing trends, favoring or disfavoring Brilinta.
Summary Table of Price Projections
| Year |
Estimated Price per Pack |
Key Notes |
| 2023 |
$220–$280 |
Stability prior to patent expiration |
| 2024 |
$150–$200 |
Initial generic entry, price drop begins |
| 2025 |
$100–$150 |
Market shifts towards generics dominate |
| 2026+ |
$100 or less |
Market largely generic, branded sales decline |
Final Observations
The future revenue potential for NDC 69238-1137 hinges on patent expiration and subsequent generic competition. Pricing will decline significantly, but early market penetration and clinical positionings could sustain some premium pricing for branded formulations in specialty markets.
Key Takeaways
- Brilinta is a leading antiplatelet drug with a 25% US market share among P2Y12 inhibitors.
- The US market for antiplatelet agents exceeds $1.75 billion annually.
- Significant price reductions are expected following patent expiration in 2024 due to generic competition.
- Long-term revenues will depend on market dynamics, clinical evidence, and regulatory policies.
- Competitive positioning and clinical differentiation are vital for sustained profitability.
FAQs
Q1: When does Brilinta’s patent expire?
A1: The patent is set to expire in 2024 in the US.
Q2: How will generic entry impact prices?
A2: Prices are projected to drop by 40–60%, potentially reducing the cost per pack to $100–$150.
Q3: What are the key competitors to Brilinta?
A3: Plavix (clopidogrel) and Effient (prasugrel) are primary competitors, with Plavix holding the largest market share.
Q4: What factors influence the future market size of Brilinta?
A4: Patent status, clinical trial outcomes, market penetration of generics, and regulatory policies.
Q5: Are new therapies expected to replace Brilinta?
A5: Yes, ongoing developments in antiplatelet and cardiovascular therapeutics could influence shifts away from Brilinta.
References
- American Heart Association. (2022). Heart disease and stroke statistics—2022 update. Circulation, 145(8), e153–e639.
- IQVIA. (2022). National Prescription Audit. IQVIA.
- U.S. Food and Drug Administration. (2020). Brilinta (ticagrelor) approval history and patent information.
- EvaluatePharma. (2022). World Preview 2022: Outlook to 2027.
- Orange Book. (2022). Approved Drug Products with Therapeutic Equivalence Evaluations.
